Who
Sherry Korczynski
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Aquestive Therapeutics.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $223K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Jun 2024
- Last trade
- 9 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 11 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $23K8,750 at $2.65 | filing |
| 9 Sep 2026filed 11 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $46K8,750 at $5.22 | filing |
| 9 Sep 2026filed 11 Sep 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,750 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,750 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $23K8,750 at $2.65 | filing |
| 9 Sep 2026filed 11 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $46K8,750 at $5.22 | filing |
| 14 Aug 2026filed 17 Aug 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $12K2,714 at $4.25 | filing |
| 14 Aug 2026filed 17 Aug 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $12K2,714 at $4.25 | filing |
| 8 Jun 2026filed 9 Jun 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | —2,714 at $0.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | —2,714 at $0.00 | filing |
| 10 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $66K15,741 at $4.17 | filing |
| 10 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $66K15,741 at $4.17 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $182K42,500 at $4.29 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $182K42,500 at $4.29 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 14 Aug 2025filed 15 Aug 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $9,6082,714 at $3.54 | filing |
| 7 Mar 2025filed 13 Apr 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 7 Mar 2025filed 13 Apr 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
News
Aquestive Therapeutics (NASDAQ:AQST) Insider Sherry Korczynski Sells 8,750 Shares of Stockthemarketsdaily.com · 12 Sep 2026Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ETAQST · manilatimes.net · 27 Oct 2026Critical Survey: Zentalis Pharmaceuticals (NASDAQ:ZNTL) versus Aquestive Therapeutics (NASDAQ:AQST)AQST · tickerreport.com · 21 Oct 2026Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA ResubmissionAQST · rttnews.com · 15 Oct 2026
1 headline in the last 90 days name Sherry Korczynski; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.